(via Thenewswire.ca)

Toronto, Ontario - April 19, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its innovative Photo Dynamic Compound (PDC) technology has been accepted for presentation at two major international scientific conferences. Acceptance at these conferences validates the significance of the technology and its efficacy in the destruction of cancer cells in research performed by Theralase's internationally acclaimed scientists.

The efficacy of the anti-cancer Photo Dynamic Compound technology will be presented at LASER World of Photonics conference in Munich, Germany on May 15, 2013.

The effective destruction of bacteria using Theralase's light activated Photo Dynamic Compound technology will be presented at Photonics North conference in Ottawa, Canada on June 3, 2013.

In further developments, Theralase's Chief Scientific Officer, Dr. Arkady Mandel has been elected to the Editorial Board of Photonics & Lasers in Medicine (PLM) journal and chosen as issue editor of PLM for the Low Level Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal, which publishes clinical and scientific studies concerned with the clinical and scientific application of lasers and biophotonics in medicine for diagnostic and therapeutic purposes. PLM recently featured the clinical success of Theralase's pivotal randomized placebo controlled clinical trial entitled, "Laser Therapy Applications for Osteoarthritis and Chronic Joint Pain."

Roger Dumoulin-White, President and CEO of Theralase said, "I am pleased that Theralase's scientific and clinical research has been recognized and acclaimed by two of the finest international scientific conferences and has been published in a peer reviewed medical journal. Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenue increases for the Company. To accelerate this process, we are actively looking to collaborate with strategic partners to further develop our technologies and increase shareholder value. Theralase's strong PDC pipeline has scientifically proven that our PDC technology is capable of consistently producing cell kill levels of 100%, even at very low concentrations, across a wide range of cancers and bacteria. In fact, our PDCs have been proven to be significantly more effective in destroying cancer cells and bacteria than currently FDA approved Photo Dynamic Compounds."

About Theralase Technologies Inc.: